Skip to main content
74°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Myriad Genetics, Inc.
< Previous
1
2
Next >
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
November 20, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
November 16, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Participate in Stephens Annual Investment Conference
November 09, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Announces Pricing of Upsized Offering of Common Stock
November 08, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock
November 08, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
November 06, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Appoints Sam Raha as Chief Operating Officer
November 01, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023
October 31, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
October 26, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
QGEN
New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood
September 28, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
September 19, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
ILMN
MYGN
Myriad Genetics Issues 2022 Environmental, Social and Governance Report
September 19, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
September 18, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work
September 06, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women
September 06, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference
September 05, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk
August 22, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Host Investor Day on September 19, 2023
August 17, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
August 15, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment
August 08, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status
August 07, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth
August 03, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023
July 27, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
July 24, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Announces New $90 Million Asset-Based Credit Facility
July 06, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
June 12, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Participate in Goldman Sachs Healthcare Conference
June 07, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023
June 01, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics
May 31, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
May 24, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.